192 related articles for article (PubMed ID: 26302462)
21. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma.
Long B; Li L; Yao L; Chen S; Yi H; Ye X; Xu D; Wu P
J Cancer Res Ther; 2015 Nov; 11 Suppl():C244-7. PubMed ID: 26612446
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of ablation of thyroid remnants with 1850 MBq iodine-131 in 67 patients with thyroid cancer.
Kawabe J; Higashiyama S; Kotani K; Yoshida A; Onoda N; Shiomi S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):68-75. PubMed ID: 27125316
[TBL] [Abstract][Full Text] [Related]
23. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.
Ladenson PW; Braverman LE; Mazzaferri EL; Brucker-Davis F; Cooper DS; Garber JR; Wondisford FE; Davies TF; DeGroot LJ; Daniels GH; Ross DS; Weintraub BD
N Engl J Med; 1997 Sep; 337(13):888-96. PubMed ID: 9302303
[TBL] [Abstract][Full Text] [Related]
24. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.
Castagna MG; Cantara S; Pacini F
J Endocrinol Invest; 2016 Oct; 39(10):1087-94. PubMed ID: 27350556
[TBL] [Abstract][Full Text] [Related]
25. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study.
Mäenpää HO; Heikkonen J; Vaalavirta L; Tenhunen M; Joensuu H
PLoS One; 2008 Apr; 3(4):e1885. PubMed ID: 18382668
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center.
Tsai JR; Wu ST; Chi SY; Yang YT; Chan YC; Lim LS; Chiew YEW; Chen WC; Chen YN; Chou CK
Kaohsiung J Med Sci; 2023 Feb; 39(2):175-181. PubMed ID: 36448726
[TBL] [Abstract][Full Text] [Related]
27. Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma.
Tamilia M; Al-Kahtani N; Rochon L; Hier MP; Payne RJ; Holcroft CA; Black MJ
Nucl Med Commun; 2011 Mar; 32(3):212-20. PubMed ID: 21191314
[TBL] [Abstract][Full Text] [Related]
28. Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective.
Sohn SY; Jang HW; Cho YY; Kim SW; Chung JH
Endocrinol Metab (Seoul); 2015 Dec; 30(4):531-42. PubMed ID: 26394733
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human thyrotropin before (131)I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials.
Lee YY; Tam KW; Lin YM; Leu WJ; Chang JC; Hsiao CL; Hsu MT; Hsieh AT
Clin Endocrinol (Oxf); 2015 Nov; 83(5):702-10. PubMed ID: 25370124
[TBL] [Abstract][Full Text] [Related]
30. Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer.
Kraenzlin ME; Meier C
Expert Opin Biol Ther; 2006 Feb; 6(2):167-76. PubMed ID: 16436042
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Reduced Radioiodine Activity for Thyroid Remnant Ablation after Total Thyroidectomy in Patients with Low to Intermediate Risk Differentiated Thyroid Carcinoma.
Todica A; Haidvogl S; Fendler WP; Ilhan H; Rominger A; Haug AR; Bartenstein P; Lehner S
Nuklearmedizin; 2017; 56(6):211-218. PubMed ID: 29533416
[TBL] [Abstract][Full Text] [Related]
32. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases.
Taïeb D; Jacob T; Zotian E; Mundler O
Thyroid; 2004 Jun; 14(6):465-7. PubMed ID: 15242576
[TBL] [Abstract][Full Text] [Related]
33. Radiation Dose-rate Reduction Pattern in Well-differentiated Thyroid Cancer Treated with I-131.
Khan SA; Khan MS; Arif M; Durr-e-Sabih ; Rahim MK; Ahmad I
J Coll Physicians Surg Pak; 2015 Jul; 25(7):510-3. PubMed ID: 26208555
[TBL] [Abstract][Full Text] [Related]
34. Effect of recombinant human thyrotropin on the uptake of radioactive iodine (¹²³I) in dogs with thyroid tumors.
Campos M; Peremans K; Vandermeulen E; Duchateau L; Bosmans T; Polis I; Daminet S
PLoS One; 2012; 7(11):e50344. PubMed ID: 23209716
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer.
Biondi B; Pulcrano M; Pagano L; Lombardi G
Biologics; 2009; 3():9-13. PubMed ID: 19707391
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with
Signore A; Campagna G; Marinaccio J; Vitis M; Lauri C; Berardinelli F; Tofani A; Chianelli M; Borro M; Gentile G; Simmaco M; Colombini F; Giovanetti A; Sgura A
J Nucl Med; 2022 Oct; 63(10):1515-1522. PubMed ID: 35115370
[TBL] [Abstract][Full Text] [Related]
37. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation.
Iakovou I; Goulis DG; Tsinaslanidou Z; Giannoula E; Katsikaki G; Konstantinidis I
Head Neck; 2016 Apr; 38 Suppl 1():E227-30. PubMed ID: 25537365
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human thyrotropin in veterinary medicine: current use and future perspectives.
Campos M; van Hoek I; Peremans K; Daminet S
J Vet Intern Med; 2012; 26(4):853-62. PubMed ID: 22676297
[TBL] [Abstract][Full Text] [Related]
39. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer.
Juweid ME; Tulchinsky M; Mismar A; Momani M; Zayed AA; Al Hawari H; Albsoul N; Mottaghy FM
Int J Cancer; 2020 Nov; 147(9):2345-2354. PubMed ID: 32319676
[TBL] [Abstract][Full Text] [Related]
40. Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy.
Kwon TE; Pasqual E; Kitahara CM; Lee C
J Radiol Prot; 2023 May; 43(2):. PubMed ID: 37196645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
